We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Bio-Rad Introduces Anti-Ipilimumab Antibodies
Product News

Bio-Rad Introduces Anti-Ipilimumab Antibodies

Bio-Rad Introduces Anti-Ipilimumab Antibodies
Product News

Bio-Rad Introduces Anti-Ipilimumab Antibodies


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Bio-Rad Introduces Anti-Ipilimumab Antibodies"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Bio-Rad Laboratories, Inc. has extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of antibodies that are specific for ipilimumab (Yervoy) and the ipilimumab/CTLA-4 drug-target complex. These highly specific and high-affinity antibodies are suitable for bioanalytical and patient drug level monitoring assays for the immune checkpoint inhibitor: ipilimumab.

Bio-Rad offers a portfolio of recombinant, monoclonal anti-idiotypic antibodies and drug-target complex binders for the development of highly selective and sensitive assays to support researchers in developing robust methods in a short timescale and generating translatable and defensible results.

Ipilimumab activates the immune system by inhibiting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), a protein receptor that hinders the destruction of cancerous cells, to treat cancers such as melanoma. The four anti-ipilimumab antibodies inhibit the binding of the drug to its target, CTLA-4, and therefore detect free drug. These antibodies are suitable for developing pharmacokinetic (PK) bridging ELISAs and being used as a surrogate positive control (or reference standard) for anti-drug antibody assays. The drug-target complex binder specifically recognizes the ipilimumab/CTLA-4 complex and can be used as the detection antibody in a PK antigen capture assay as an alternative format to the bridging ELISA.

The recombinant monoclonal anti-idiotypic antibodies are generated using the Human Combinatorial Antibody Library (HuCAL®) and CysDisplay®, a proprietary method of phage display with guided selection methods to obtain highly targeted reagents. The recombinant production method also ensures a consistent and secure supply.

“Bio-Rad’s offering of anti-idiotypic antibodies continues to grow and is one of the largest portfolios available that includes antibodies targeting immune checkpoint inhibitor drugs: nivolumab and pembrolizumab and now, ipilimumab,” said Amanda Turner, Bio-Rad Product Manager, Life Science Group. “The in vitro production means researchers can rely on our highly specific and high affinity recombinant monoclonal antibodies to deliver consistent results across PK assays,” she added.

The anti-ipilimumab antibodies are approved for in vitro research and for commercial applications of in vitro testing services that support preclinical and clinical drug and biosimilar development and patient monitoring.

Advertisement